1
|
Chat VS, Ellebrecht CT, Kingston P, Bell S, Gondo G, Cordoro KM, Desai SR, Duffin KC, Feldman SR, Garg A, Gelfand JM, Gladman D, Green LJ, Gudjonsson J, Han G, Hawkes JE, Kircik L, Koo J, Langley R, Lebwohl M, Michael Lewitt G, Liao W, Martin G, Orbai AM, Reddy SM, Richardson V, Ritchlin CT, Schwartzman S, Siegel EL, Van Voorhees AS, Wallace EB, Weinberg JM, Winthrop KL, Yamauchi P, Armstrong AW. Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2024:S0190-9622(24)00243-3. [PMID: 38331098 DOI: 10.1016/j.jaad.2023.12.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 10/30/2023] [Accepted: 12/05/2023] [Indexed: 02/10/2024]
Abstract
BACKGROUND For psoriatic patients who need to receive non-live or live vaccines, evidence-based recommendations are needed regarding whether to pause or continue systemic therapies for psoriasis and/or psoriatic arthritis. OBJECTIVE To evaluate literature regarding vaccine efficacy and safety and to generate consensus-based recommendations for adults receiving systemic therapies for psoriasis and/or psoriatic arthritis receiving non-live or live vaccines. METHODS Using a modified Delphi process, 22 consensus statements were developed by the National Psoriasis Foundation Medical Board and COVID-19 Task Force, and infectious disease experts. RESULTS Key recommendations include continuing most oral and biologic therapies without modification for patients receiving non-live vaccines; consider interruption of methotrexate for non-live vaccines. For patients receiving live vaccines, discontinue most oral and biologic medications before and after administration of live vaccine. Specific recommendations include discontinuing most biologic therapies, except for abatacept, for 2-3 half-lives before live vaccine administration and deferring next dose 2-4 weeks after live vaccination. LIMITATIONS Studies regarding infection rates after vaccination are lacking. CONCLUSION Interruption of anti-psoriatic oral and biologic therapies is generally not necessary for patients receiving non-live vaccines. Temporary interruption of oral and biologic therapies before and after administration of live vaccines is recommended in most cases.
Collapse
Affiliation(s)
- Vipawee S Chat
- Department of Dermatology, Keck School of Medicine at USC, Los Angeles, California
| | - Christoph T Ellebrecht
- Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Paige Kingston
- Department of Dermatology, Keck School of Medicine at USC, Los Angeles, California
| | - Stacie Bell
- National Psoriasis Foundation, Portland, Oregon
| | | | - Kelly M Cordoro
- Department of Dermatology, University of California, San Francisco School of Medicine, San Francisco, California
| | - Seemal R Desai
- Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas; Innovative Dermatology, Plano, Texas
| | | | - Steven R Feldman
- Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Amit Garg
- Department of Dermatology, Donald and Barbara Zucker School of Medicine, Hempstead, New York
| | - Joel M Gelfand
- Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Dafna Gladman
- Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada
| | | | - Johann Gudjonsson
- Department of Dermatology, University of Michigan, Ann Arbor, Michigan
| | - George Han
- Department of Dermatology, Donald and Barbara Zucker School of Medicine, Hempstead, New York
| | - Jason E Hawkes
- Department of Dermatology, University of California, Davis, Rocklin, California
| | | | - John Koo
- Department of Dermatology, University of California, San Francisco School of Medicine, San Francisco, California
| | - Richard Langley
- Division of Clinical Dermatology & Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Mark Lebwohl
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
| | | | - Wilson Liao
- Department of Dermatology, University of California, San Francisco School of Medicine, San Francisco, California
| | - George Martin
- Dr. George Martin Dermatology Associates, Kihei, Hawaii
| | - Ana-Maria Orbai
- Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Soumya M Reddy
- Division of Rheumatology, NYU Grossman School of Medicine, New York, New York
| | - Veronica Richardson
- Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Christopher T Ritchlin
- Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY
| | - Sergio Schwartzman
- Division of Rheumatology, Weill Cornell Medical Center, New York, New York
| | - Evan L Siegel
- Department of Rheumatology, Arthritis and Rheumatism Associates, Rockville, Maryland
| | - Abby S Van Voorhees
- Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia
| | - Elizabeth B Wallace
- Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Jeffrey M Weinberg
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Kevin L Winthrop
- Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon
| | - Paul Yamauchi
- Dermatology Institute & Skin Care Center, Santa Monica, California
| | - April W Armstrong
- Division of Dermatology, University of California Los Angeles, Los Angeles, California.
| |
Collapse
|
2
|
Warner B, Pranzatelli T, Perez P, Ku A, Matuck BF, Huynh K, Sakai S, Abed M, Jang SI, Yamada E, Dominick K, Ahmed Z, Oliver A, Wasikowski R, Easter Q, Magone MT, Baer A, Pelayo E, Khavandgar Z, Gupta S, Kleiner D, Lessard C, Farris A, Martin D, Morell R, Zheng C, Rachmaninoff N, Maldonado-Ortiz J, Qu X, Aure M, Dezfulian M, Lake R, Teichmann S, Barber D, Tsoi L, Sowalsky A, Tyc K, Gudjonsson J, Byrd K, Johnson P, Liu J, Chiorini J. GZMK+CD8+ T cells Target a Specific Acinar Cell Type in Sjögren's Disease. Res Sq 2023:rs.3.rs-3601404. [PMID: 38196575 PMCID: PMC10775371 DOI: 10.21203/rs.3.rs-3601404/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2024]
Abstract
Sjögren's Disease (SjD) is a systemic autoimmune disease without a clear etiology or effective therapy. Utilizing unbiased single-cell and spatial transcriptomics to analyze human minor salivary glands in health and disease we developed a comprehensive understanding of the cellular landscape of healthy salivary glands and how that landscape changes in SjD patients. We identified novel seromucous acinar cell types and identified a population of PRR4+CST3+WFDC2- seromucous acinar cells that are particularly targeted in SjD. Notably, GZMK+CD8 T cells, enriched in SjD, exhibited a cytotoxic phenotype and were physically associated with immune-engaged epithelial cells in disease. These findings shed light on the immune response's impact on transitioning acinar cells with high levels of secretion and explain the loss of this specific cell population in SjD. This study explores the complex interplay of varied cell types in the salivary glands and their role in the pathology of Sjögren's Disease.
Collapse
Affiliation(s)
- Blake Warner
- National Institute of Dental and Craniofacial Research
| | | | | | - Anson Ku
- Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute
| | | | | | | | - Mehdi Abed
- Salivary Disorders Unit, National Institute of Dental and Craniofacial Research
| | | | - Eiko Yamada
- Salivary Disorders Unit, National Institute of Dental and Craniofacial Research
| | - Kalie Dominick
- Salivary Disorders Unit, National Institute of Dental and Craniofacial Research
| | - Zara Ahmed
- Salivary Disorders Unit, National Institute of Dental and Craniofacial Research
| | | | | | | | | | - Alan Baer
- Sjögren's Clinical Investigations Team, National Institute of Dental and Craniofacial Research
| | | | - Zohreh Khavandgar
- Sjögren's Clinical Investigations Team, National Institute of Dental and Craniofacial Research
| | - Sarthak Gupta
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
| | - David Kleiner
- Laboratory of Pathology, Center for Cancer Research, National Cancer Institute
| | - Christopher Lessard
- Genes & Human Disease Research Program, Oklahoma Medical Research Foundation
| | - A Farris
- Oklahoma Medical Research Fd. OMRF
| | | | - Robert Morell
- Genomics and Computational Biology Core, National Institutes on Deafness and Other Communication Disorders, NIH
| | - Changyu Zheng
- Genomics and Computational Biology Core, National Institute of Dental and Craniofacial Research
| | | | | | - Xufeng Qu
- Massey Cancer Center, Virginia Commonwealth University
| | - Marit Aure
- Matrix and Morphogenesis Section, National Institute of Dental and Craniofacial Research
| | | | - Ross Lake
- Laboratory of Genitourinary Cancer Pathogenesis (LCGP) Microscopy Core Facility, Center for Cancer Research, National Cancer Institute
| | | | - Daniel Barber
- T-lymphocyte Biology Section, National Institute of Allergy and Infectious Diseases
| | - Lam Tsoi
- Medical University of South Carolina
| | | | - Katarzyna Tyc
- Department of Biostatistics, Virginia Commonwealth University
| | | | - Kevin Byrd
- Lab of Oral & Craniofacial Innovation (LOCI), Department of Innovation & Technology Research, ADA Science & Research Institute
| | - Philip Johnson
- Department of Biology, University of Maryland College Park
| | | | - John Chiorini
- National Institute of Dental and Craniofacial Research
| |
Collapse
|
3
|
Kovalchin CE, Kaffenberger J, Trinidad J, Gilkey TW, Minta A, Gudjonsson J, Kaffenberger BH. Characterizing risk factors for hospitalization for psoriasis patients. Arch Dermatol Res 2023; 315:1541-1546. [PMID: 36662322 DOI: 10.1007/s00403-023-02533-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 12/08/2022] [Accepted: 01/10/2023] [Indexed: 01/21/2023]
Abstract
Psoriasis is a chronic autoimmune disease with a large economic impact. Inpatient care is a significant expense, and about one-third of patients admitted for psoriasis are readmitted. Reducing hospitalizations and readmissions is an important goal for improving outcomes for psoriasis patients. The objective of this study is to characterize patients who are hospitalized for psoriasis, and differentiate features for patients with a single hospitalization from those who were hospitalized multiple times during the study period. Hospitalized psoriasis patients were identified from an in-patient database at a single academic institution. Differences between psoriasis patients with one hospitalization and those with multiple hospitalizations were characterized, as were differences between patients who were hospitalized primarily for psoriasis and those who were admitted primarily for other reasons. Patients who were primarily hospitalized for psoriasis had fewer comorbidities, shorter hospitalizations, and a lower death rate than those hospitalized for other reasons. Patients with multiple hospitalizations had more comorbidities and worse outcomes than patients with a single hospitalization. Patients who are hospitalized primarily for psoriasis are more likely to be pustular, and tend to have fewer comorbidities and better outcomes than patients with psoriasis who are hospitalized with psoriasis as a secondary diagnosis. One limitation of this study is the lack of data available to consistently quantify disease severity, such as percent of body surface area affected by psoriasis or Physician's Global Assessment score.
Collapse
Affiliation(s)
| | - Jessica Kaffenberger
- Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 2012 Kenny Road, Columbus, OH, 43221, USA
| | - John Trinidad
- Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 2012 Kenny Road, Columbus, OH, 43221, USA
| | - Ty W Gilkey
- The Ohio State University College of Medicine, Columbus, OH, USA
| | - Abena Minta
- The Ohio State University College of Medicine, Columbus, OH, USA
| | - Johann Gudjonsson
- Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Benjamin H Kaffenberger
- Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, 2012 Kenny Road, Columbus, OH, 43221, USA.
| |
Collapse
|
4
|
Mangum KD, Audu CO, Barrett E, Joshi A, Obi AT, Gudjonsson J, Moore B, Davis FM, Gallagher K. IFNβ Regulates Abdominal Aortic Aneurysm Formation By Modulating Expression Of The Histone Methyltransferase SETDB2. J Vasc Surg 2022. [DOI: 10.1016/j.jvs.2022.07.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Hesson A, Plazyo O, Gudjonsson J, Langen E, Ganesh S. Abstract P043: Preeclampsia Superimposed On Chronic Hypertension: Evidence For A Hormone-mediated, Lasting Effect On Antihypertensive Needs. Hypertension 2022. [DOI: 10.1161/hyp.79.suppl_1.p043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective:
To characterize clinical and molecular differences between chronic hypertension (HTN), preeclampsia superimposed on chronic hypertension (SI), and isolated pregnancy induced hypertension (PIH).
Methods:
Individuals with HTN, SI, or PIH who had a livebirth between 2017 and 2020 were identified in an obstetric biorepository. Medical histories were reviewed. Paraffin-embedded placental samples (N=36; N
HTN
=13, N
SI
=7, N
PIH
=16) were submitted for bulk RNA sequencing along with matched non-hypertensive controls (N=12). Differential gene expression was assessed for the HTN, SI, and PIH samples relative to the controls; transcripts with significant differences (P
adj
<0.05) underwent Gene Ontology analysis.
Results:
Chronic hypertension was present in 28.6% (N=40/140) of the sample; 37.5% (N=15/40) developed SI. Those with SI were more likely to require additional peripartum antihypertensive therapy than with those with PIH (P<0.01). They also had lower rates of antihypertensive down-titration or discontinuation at 6 weeks postpartum (P=0.01). Placental samples demonstrated a hormone-mediated mechanism for these differences with gonadotropin secretion and regulation differences in the transcriptomic signature of SI. Growth factors and mediators of placental development were differentially expressed in HTN and PIH (Figure 1).
Conclusion:
SI has longer-lasting effects on hypertension trajectory than PIH. Placentally mediated differences in sex hormone dysregulation may underlie clinical differences in antihypertensive needs.
Figure 1
Gene ontology results with Bonferroni-corrected significance threshold.
Collapse
|
6
|
Barbieux C, Bonnet-des-Claustres M, Fahrner M, Tsoi L, Gouin O, Petrova E, Bourrat E, Schilling O, Gudjonsson J, Hovnanian A. 228 IL-36 is a hallmark of Netherton syndrome with type I IFN, Th2 and Th9 responses distinguishing its dual clinical presentation. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Hesson A, Langen ES, Plazyo O, Gudjonsson J, Ganesh S. 76 The Transcriptome of Hypertensive Placentas: Superimposed preeclampsia as a transcriptionally distinct condition. Am J Obstet Gynecol 2021. [DOI: 10.1016/j.ajog.2020.12.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Billi A, Gharaee-Kermani M, Fullmer J, Tsoi A, Hill B, Gruszka D, Ludwig J, Xing X, Estadt S, Wolf S, Rizvi S, Berthier C, Hodgin J, Beamer M, Sarkar M, Uppala R, Shao S, Harms P, Verhaegen M, Voorhees J, Wen F, Ward N, Dlugosz A, Kahlenberg M, Gudjonsson J. 640 The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Patrick M, Stuart P, Yin X, He Z, Gudjonsson J, Voorhees J, Nair R, Liu D, Elder J, Tsoi L. 059 Trans-disease meta-analysis between psoriasis and type 2 diabetes reveals shared genetic signals. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Uppala R, Sarkar M, Zeng C, Stoll S, Tsoi L, Shao S, Billi A, Kahlenberg M, Gudjonsson J. 069 Generation and utilization of a stable IFN response reporter line in keratinocytes. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Sarkar M, Uppala R, Shao S, Kahlenberg M, Gudjonsson J. 386 Autocrine IFN-k restricts CRISPR-Cas9 keratinocyte transfection. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Le ST, Merleev AA, Luxardi G, Shimoda M, Adamopoulos IE, Tsoi LC, Wang JZ, Alexanian C, Raychaudhuri SP, Hwang ST, Gudjonsson J, Marusina AI, Maverakis E. 2D Visualization of the Psoriasis Transcriptome Fails to Support the Existence of Dual-Secreting IL-17A/IL-22 Th17 T Cells. Front Immunol 2019; 10:589. [PMID: 31019502 PMCID: PMC6458264 DOI: 10.3389/fimmu.2019.00589] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2018] [Accepted: 03/05/2019] [Indexed: 12/15/2022] Open
Abstract
The present paradigm of psoriasis pathogenesis revolves around the IL-23/IL-17A axis. Dual-secreting Th17 T cells presumably are the predominant sources of the psoriasis phenotype-driving cytokines, IL-17A and IL-22. We thus conducted a meta-analysis of independently acquired RNA-seq psoriasis datasets to explore the relationship between the expression of IL17A and IL22. This analysis failed to support the existence of dual secreting IL-17A/IL-22 Th17 cells as a major source of these cytokines. However, variable relationships amongst the expression of psoriasis susceptibility genes and of IL17A, IL22, and IL23A were identified. Additionally, to shed light on gene expression relationships in psoriasis, we applied a machine learning nonlinear dimensionality reduction strategy (t-SNE) to display the entire psoriasis transcriptome as a 2-dimensonal image. This analysis revealed a variety of gene clusters, relevant to psoriasis pathophysiology but failed to support a relationship between IL17A and IL22. These results support existing theories on alternative sources of IL-17A and IL-22 in psoriasis such as a Th22 cells and non-T cell populations.
Collapse
Affiliation(s)
- Stephanie T. Le
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
| | - Alexander A. Merleev
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
| | - Guillaume Luxardi
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
| | - Michiko Shimoda
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
| | - Iannis E. Adamopoulos
- Division of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, University of California, Davis, Sacramento, CA, United States
| | - Lam C. Tsoi
- Department of Dermatology, University of Michigan, Ann Arbor, MI, United States
- Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, United States
| | - Jenny Z. Wang
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
- Albert Einstein College of Medicine, Bronx, NY, United States
| | - Claire Alexanian
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
- Georgetown University School of Medicine, Washington, DC, United States
| | - Siba P. Raychaudhuri
- Division of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, University of California, Davis, Sacramento, CA, United States
- Department of Veterans Affairs, VA Sacramento Medical Center, Northern California Health Care System, Mather, CA, United States
| | - Samuel T. Hwang
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
| | - Johann Gudjonsson
- Department of Dermatology, University of Michigan, Ann Arbor, MI, United States
| | - Alina I. Marusina
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
| | - Emanual Maverakis
- Department of Dermatology, University of California, Davis, Sacramento, CA, United States
| |
Collapse
|
13
|
Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, Raelson JV, Belouchi M, Fournier H, Reinhard C, Ding J, Li Y, Tejasvi T, Gudjonsson J, Stoll SW, Voorhees JJ, Lambert S, Weidinger S, Eberlein B, Kunz M, Rahman P, Gladman DD, Gieger C, Wichmann HE, Karlsen TH, Mayr G, Albrecht M, Kabelitz D, Mrowietz U, Abecasis GR, Elder JT, Schreiber S, Weichenthal M, Franke A. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010; 42:991-5. [PMID: 20953188 DOI: 10.1038/ng.689] [Citation(s) in RCA: 283] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2010] [Accepted: 07/26/2010] [Indexed: 12/22/2022]
Abstract
Psoriasis is a multifactorial skin disease characterized by epidermal hyperproliferation and chronic inflammation, the most common form of which is psoriasis vulgaris (PsV). We present a genome-wide association analysis of 2,339,118 SNPs in 472 PsV cases and 1,146 controls from Germany, with follow-up of the 147 most significant SNPs in 2,746 PsV cases and 4,140 controls from three independent replication panels. We identified an association at TRAF3IP2 on 6q21 and genotyped two SNPs at this locus in two additional replication panels (the combined discovery and replication panels consisted of 6,487 cases and 8,037 controls; combined P = 2.36 × 10⁻¹⁰ for rs13210247 and combined P = 1.24 × 10⁻¹⁶ for rs33980500). About 15% of psoriasis cases develop psoriatic arthritis (PsA). A stratified analysis of our datasets including only PsA cases (1,922 cases compared to 8,037 controls, P = 4.57 × 10⁻¹² for rs33980500) suggested that TRAF3IP2 represents a shared susceptibility for PsV and PsA. TRAF3IP2 encodes a protein involved in IL-17 signaling and which interacts with members of the Rel/NF-κB transcription factor family.
Collapse
Affiliation(s)
- Eva Ellinghaus
- Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|